COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01181830
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : October 16, 2013
Information provided by (Responsible Party):
Cristiano Fava, Universita di Verona

Brief Summary:

Magnesium is the second most abundant ion in human cells and plays fundamental roles in several enzymatic reactions: it is involved in ATP production, in the phosphorylation of proteins, in glucose metabolism and in the contraction of cytoskeleton.

Several epidemiological studies demonstrated that low dietary magnesium intake is inversely associated with diabetes mellitus, hypertension and metabolic syndrome.

Magnesium could be related to important haemodynamic and metabolic anomalies: at vascular level it acts as an antagonist of calcium, especially in vascular smooth muscle cells, thus its deficit could enhance vascular contraction; with regard to glucose metabolism, magnesium is involved in the physiopathological mechanism of insulin resistance, through a reduction in cellular uptake of glucose. This condition and the subsequent compensatory hyperinsulinemia can ultimately lead to increased synthesis of proinflammatory cytokines and to endothelial dysfunction. Thus, magnesium depletion and subsequent alterations can increase the risk of developing vascular disease such as atherosclerosis and has been associated with cardiovascular events.

Several clinical trials have explored the possible beneficial effect of magnesium supplementation on blood pressure, plasma lipids and insulin resistance but the results are often contradictory. One of the possibilities for these unclear results could be that in some of them the interventions started too late when haemodynamic and metabolic changes are more difficult to revert.

The investigators hypothesis is that magnesium supplementation in a population at increased genetic risk of developing metabolic syndrome but without it could improve blood pressure and the other metabolic syndrome related components.

Thus, the aim of the present study is to evaluate the effect of oral supplementation of magnesium (16.2 mmol/day of magnesium pidolate) on metabolic syndrome's components in a sample of 15 subjects who are at increased risk of developing metabolic syndrome since have a positive familiar history of type II diabetes mellitus and/or metabolic syndrome(AHA/NHLBI criteria).

Condition or disease Intervention/treatment Phase
Family History of Metabolic Syndrome Family History of Diabetes Drug: magnesium pidolate Drug: placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome
Study Start Date : February 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Magnesium

Arm Intervention/treatment
Active Comparator: magnesium pidolate
administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
Drug: magnesium pidolate
administration of 8.1 mmol bid of magnesium pidolate

Placebo Comparator: placebo
administration of 8.1 mmol bid of placebo for 8 weeks
Drug: placebo
administration of 8.1 mmol bid of placebo

Primary Outcome Measures :
  1. Blood pressure [ Time Frame: 8 weeks ]
    Blood pressure measured in the lying and standing position (average of three measurements);

Secondary Outcome Measures :
  1. other features of metabolic syndrome [ Time Frame: 8 weeks ]
    especially plasma lipids and HOMA index

  2. endothelial function [ Time Frame: 8 weeks ]
    endothelial function as measured non-invasively by ultrasound using the "Flow Mediated Dilatation" (FMD) technique

  3. arterial stiffness [ Time Frame: 8 weeks ]
    systemic and local arterial stiffness measured by digital photoplethysmography and by carotid ultrasound

  4. Inflammation [ Time Frame: 8 weeks ]
    Markers of inflammation such as C reactive protein

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • positive family history of type II diabetes mellitus and/or metabolic syndrome(AHA/NHLBI criteria).

Exclusion Criteria:

  • any therapy related to metabolic syndrome (that is antihypertensive, anti diabetic, antilipemic drugs);
  • age < 18 years or >50 years;
  • previously diagnosed hypertension or immediate need for antihypertensive therapy (BP≥160/100);
  • diabetes mellitus (ADA criteria);
  • obesity (BMI>30Kg/m2);
  • Continuative use of NSAIDs, magnesium or vitamin supplements;
  • Hypermagnesaemia;
  • Previous cardio- or cerebrovascular events;
  • chronic kidney or liver or inflammatory or neoplastic disease;
  • gastrointestinal dysfunction with hypomotility;
  • active smoke (>5 cigarettes per day);
  • Impossibility to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01181830

Layout table for location information
Azienda Ospedaliera Universitaria Integrata - Division of Internal Medicine C
Verona, VR, Italy, 37134
Sponsors and Collaborators
Universita di Verona
Layout table for investigator information
Principal Investigator: Pietro Delva, MD Universita of Verona
Principal Investigator: Cristiano Fava, MD, PhD Universita of Verona
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Cristiano Fava, MD, PhD, Universita di Verona Identifier: NCT01181830    
Other Study ID Numbers: CF_Mg_fam_MetS
First Posted: August 13, 2010    Key Record Dates
Last Update Posted: October 16, 2013
Last Verified: October 2013
Keywords provided by Cristiano Fava, Universita di Verona:
metabolic syndrome
family history
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Metabolic Syndrome
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Resistance